Literature DB >> 31421151

Radiation-Related Toxicities Using Organ Sparing Total Marrow Irradiation Transplant Conditioning Regimens.

Ashwin Shinde1, Dongyun Yang2, Paul Frankel2, An Liu1, Chunhui Han1, Bianca Del Vecchio2, Timothy Schultheiss1, Jonathan Cheng1, Richard Li1, Daniel Kim1, Eric H Radany1, Susanta Hui1, George Somlo3, Joseph Rosenthal4, Anthony Stein5, Stephen Forman5, Jeffrey Y C Wong6.   

Abstract

PURPOSE: Toxicities after organ sparing myeloablative total marrow irradiation (TMI) conditioning regimens have not been well characterized. The purpose of this study is to report pulmonary, renal, thyroid, and cataract toxicities from a prospective trial monitoring patients up to 8 years after TMI. METHODS AND MATERIALS: A total of 142 patients with primarily multiple myeloma or acute leukemia undergoing hematopoietic cell transplantation were evaluated. Follow-up included pulmonary function tests, serum creatinine, glomerular filtration rate, thyroid panel, and ophthalmologic examinations performed at 100 days, 6 months, and annually. Median TMI dose was 14 Gy (10-19 Gy) delivered at 1.5 to 2.0 Gy twice per day at a dose-rate of 200 cGy/min.
RESULTS: Median age was 52 years (range 9-70). Median follow-up (range) for all patients was 2 years (0-8) and for patients alive at the time of last follow-up (n = 50), 5.5 years (0-8). Mean organ doses in Gy were lung 7.0, kidneys 7.1, thyroid 6.7, and lens 2.8. The crude incidence of radiation pneumonitis (RP) was 1 of 142 (0.7%). The cumulative incidence of infection and RP (I/RP) was 22.7% at 2 years post-TMI. Mean lung dose ≤8 Gy predicted for significantly lower rates of I/RP (2-year cumulative incidence 20.8% vs 31.8%, P = .012). No radiation-induced renal toxicity was noted. Hypothyroidism occurred in 6.0% and cataract formation in 7.0% of patients.
CONCLUSIONS: TMI delivered with intensity modulated radiation therapy results in lower organ doses and was associated with fewer toxicities compared with historical cohorts treated with conventional total body irradiation. Keeping the mean lung dose to 8 Gy or less was associated with lower pulmonary complications. Further evaluation in clinical trials of intensity modulated radiation therapy to deliver TMI, total marrow and lymphoid irradiation, and organ sparing conformal total body irradiation is warranted.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31421151     DOI: 10.1016/j.ijrobp.2019.08.010

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

Review 1.  All for one, though not one for all: team players in normal tissue radiobiology.

Authors:  Marjan Boerma; Catherine M Davis; Isabel L Jackson; Dörthe Schaue; Jacqueline P Williams
Journal:  Int J Radiat Biol       Date:  2021-07-01       Impact factor: 2.694

2.  A novel nomogram containing acute radiation esophagitis predicting radiation pneumonitis in thoracic cancer receiving radiotherapy.

Authors:  Wenjie Tang; Xiaolin Li; Haining Yu; Xiaoyang Yin; Bing Zou; Tingting Zhang; Jinlong Chen; Xindong Sun; Naifu Liu; Jinming Yu; Peng Xie
Journal:  BMC Cancer       Date:  2021-05-22       Impact factor: 4.430

3.  Safety of total body irradiation using intensity-modulated radiation therapy by helical tomotherapy in allogeneic hematopoietic stem cell transplantation: a prospective pilot study.

Authors:  Tatsuya Konishi; Hiroaki Ogawa; Yuho Najima; Shinpei Hashimoto; Atsushi Wada; Hiroto Adachi; Ryosuke Konuma; Yuya Kishida; Akihito Nagata; Yuta Yamada; Satoshi Kaito; Junichi Mukae; Atsushi Marumo; Yuma Noguchi; Takashi Toya; Aiko Igarashi; Takeshi Kobayashi; Kazuteru Ohashi; Noriko Doki; Katsuyuki Karasawa
Journal:  J Radiat Res       Date:  2020-11-16       Impact factor: 2.724

4.  The Burden of Survivorship on Hematological Patients-Long-Term Analysis of Toxicities after Total Body Irradiation and Allogeneic Stem Cell Transplantation.

Authors:  Michael Oertel; Jonas Martel; Jan-Henrik Mikesch; Sergiu Scobioala; Christian Reicherts; Kai Kröger; Georg Lenz; Matthias Stelljes; Hans Theodor Eich
Journal:  Cancers (Basel)       Date:  2021-11-11       Impact factor: 6.639

Review 5.  Pulmonary Toxicity After Total Body Irradiation - Critical Review of the Literature and Recommendations for Toxicity Reporting.

Authors:  Jennifer Vogel; Susanta Hui; Chia-Ho Hua; Kathryn Dusenbery; Premavarthy Rassiah; John Kalapurakal; Louis Constine; Natia Esiashvili
Journal:  Front Oncol       Date:  2021-08-26       Impact factor: 6.244

Review 6.  Total Body Irradiation in Haematopoietic Stem Cell Transplantation for Paediatric Acute Lymphoblastic Leukaemia: Review of the Literature and Future Directions.

Authors:  Bianca A W Hoeben; Jeffrey Y C Wong; Lotte S Fog; Christoph Losert; Andrea R Filippi; Søren M Bentzen; Adriana Balduzzi; Lena Specht
Journal:  Front Pediatr       Date:  2021-12-03       Impact factor: 3.418

7.  Target Coverage and Normal Organ Sparing in Dose-Escalated Total Marrow and Lymphatic Irradiation: A Single-Institution Experience.

Authors:  Chunhui Han; An Liu; Jeffrey Y C Wong
Journal:  Front Oncol       Date:  2022-07-26       Impact factor: 5.738

8.  Clinical study of total bone marrow combined with total lymphatic irradiation pretreatment based on tomotherapy in hematopoietic stem cell transplantation of acute leukemia.

Authors:  Fanyang Kong; Shuaipeng Liu; Lele Liu; Yifei Pi; Yuntong Pei; Dandan Xu; Fei Jia; Bin Han; Yuexin Guo
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

9.  Fractionated Total Body Irradiation on an Infant Using Tomotherapy.

Authors:  Usha Abraham; Tino Romaguera; Ranjini Tolakanahalli; Alonso N Gutierrez; Matthew Hall
Journal:  Cureus       Date:  2022-08-18

10.  Pulmonary Toxicity after Total Body Irradiation-An Underrated Complication? Estimation of Risk via Normal Tissue Complication Probability Calculations and Correlation with Clinical Data.

Authors:  Michael Oertel; Christopher Kittel; Jonas Martel; Jan-Henrik Mikesch; Marco Glashoerster; Matthias Stelljes; Hans Theodor Eich
Journal:  Cancers (Basel)       Date:  2021-06-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.